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DISTANCE TO TREATMENT CENTER AND OTHER NON-MEDICAL 
FACTORS THAT CAN INFLUENCE PEDIATRIC CANCER SURVIVAL 
DANIEL PATRICK KELLY 
ABSTRACT 
Background: A major component in determining the prognosis for all pediatric cancers 
is the biology of specific malignancies.  However, it has also been found that non-
medical factors such as distance between home and treatment center, rural versus urban 
residence, and socioeconomic status can influence pediatric cancer survival.  Relatively 
few studies have been done in this area.  
Aims: This study attempted to evaluate whether there are disparities in pediatric cancer 
survival outcomes in North Carolina (NC) based on geography.  Other demographic 
characteristics of the patients were also examined, including race, ethnicity, sex, and 
county of residence.  
Methods:  A retrospective, single-institution study at the University of North Carolina  
(UNC) Hospital was performed using a clinical database.  Eligibility was limited to 
patients 0-21 years of age who were diagnosed with acute myeloid leukemia, acute 
lymphoblastic leukemia, central nervous system tumors, neuroblastoma, 
rhabdomyosarcoma, or Wilms tumor between the years 2000 and 2018 who were NC 
residents and treated at UNC Hospital.  
Results:  Distance to the UNC Hospital from a patient’s residence did not have a 
statistically significant impact on pediatric cancer survival outcomes.  However, patients 
vi 
living in non-metropolitan areas had lower survival outcomes when compared to patients 
residing in metropolitan regions.  Patients who were African Americans and “Other” 
races had lower survival outcomes when compared to Whites.  
Conclusions:  Although this study indicates no significant association between distance 
to the UNC Hospital and pediatric cancer survival outcome, patient race and metropolitan 
classification of a patient’s county of residence appear to be linked with survival 
disparities.  
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 INTRODUCTION 	
In the United States (US), approximately 15000 children and adolescents aged  
0-19 years are diagnosed with cancer each year (“Cancer Statistics,” 2018).  Of these 
cases, approximately 20% will die from their malignancy, making cancer the second 
leading cause of death for children in the US, behind accidents (“Cancer Statistics,” 
2018; “Cancer in Children and Adolescents,” 2018).  However, childhood cancer is a 
diverse entity that includes many different types of cancers, and survival statistics vary 
greatly depending in large part on the exact diagnosis (“Cancer in Children and 
Adolescents,” 2018).  The most common types of pediatric cancers include leukemias 
and central nervous system (CNS) tumors, which account for over half of all childhood 
cancer diagnoses each year (“Cancers that Develop in Children,” 2016).  Data on the 
relative frequency of pediatric cancer diagnoses are shown in the Figure 1.  
 
 
 
 
 
 
 
Figure 1. Approximate percentage of pediatric cancer diagnoses by type in the US.  This 
figure shows the relative number of common pediatric cancer diagnoses in relation to all 
pediatric cancer diagnoses.  Data taken from the American Cancer Society (“Cancers that 
Develop in Children,” 2016).  CNS= central nervous system. 
Pediatric Cancer Diagnoses 
Leukemias- 30% 
CNS tumors- 26% 
Neuroblastoma- 6% 
Wilms tumor- 5% 
Hodgkin Lymphoma- 3% 
Non-Hodgkin Lymphoma- 5% 
Rhabdomyosarcoma- 3% 
Retinoblastoma- 2% 
Bone cancers- 3% 
Other- 17% 
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Survival rates across many different types of pediatric cancers have greatly 
improved over the last several decades as researchers and clinicians have developed a 
better understanding of this group of diseases and created more effective treatments 
(Burkhamer, Kriebel, & Clapp, 2017).  A major factor in determining the prognosis for 
all pediatric cancers is the biology of specific malignancies reflected in cancer histology, 
molecular markers, and stage at diagnosis (“Cancer in Children and Adolescents,” 2018).  
However, some studies have found that other variables can also influence a child’s cancer 
prognosis.  These variables include factors that may relate to ease of delivery of care, 
such as distance between home and treatment center, rural versus urban residence, and 
socioeconomic status (SES) (Austin et al., 2015; Carriere et al., 2018; Lindley & Oyana, 
2016). 
One international meta-analysis study found an association between area of 
residence and cancer survival outcomes worldwide (Carriere et al., 2018).  Of 39 
different studies conducted in the US, Europe, and Australia, 30 reported that children 
living in non-metropolitan areas had a survival disadvantage, whereas five found no 
difference, two found that those living in rural areas had better survival outcomes, and the 
remaining two reported mixed results (Carriere et al., 2018).  One state-based study from 
Tennessee examined how geographic residence and race impacted mortality rates among 
pediatric cancer patients between the years 2004 and 2011 (Lindley & Oyana, 2016).  
The investigators analyzed their data based on each racial group’s proximity to rural 
areas along with “clusters of mortality,” which were defined as whether the child lived 
within 10 miles of an area with a higher relative concentration of pediatric oncology 
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patient deaths (Lindley & Oyana, 2016).  The research team concluded that African 
American children were more likely to live in rural areas that are far from treatment 
centers as well as live closer to a “cluster of mortality” compared to other racial groups 
(Lindley & Oyana, 2016). 
Interestingly, other limited published information on outcomes of pediatric 
cancers as a function of home location has not verified these observations.  A Texas 
study, which reviewed the medical records of children diagnosed with non-CNS solid 
tumors between 1995 and 2009, determined that there was no significant association 
between distance to treatment and a patient’s survival outcome (Austin et al., 2015).  The 
investigators did find that racial and ethnic differences can influence pediatric cancer 
survival outcomes even when the tumor biology is the same (Austin et al., 2015).  In that 
work, Hispanic and non-Hispanic African Americans were more likely to present with 
metastatic disease at diagnosis compared to other races and ethnicities, and metastatic 
disease was associated with a worse survival (Austin et al., 2015).  Furthermore, another 
study reviewed pediatric cancer survival rates across the US from 2000 to 2010 using 
data from the Surveillance, Epidemiology, and End Results (SEER) Program and then 
compared the results between rural and urban areas (Delavar, Feng, & Johnson, 2018). 
The study concluded there was no association between rural or urban residence and 
pediatric cancer survival outcome (Delavar et al., 2018).  The authors speculated that the 
similar outcomes might have been due to the high rates of health insurance among 
children and adolescents as well as the extensive network of pediatric cancer specialists 
in the areas studied (Delavar et al., 2018).   
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To the author’s knowledge, no studies have looked at pediatric cancer outcomes 
in North Carolina (NC) as a function of location.  However, one study of adult patients 
with acute myeloid leukemia (AML) in NC focused on the effect of distance to a cancer 
center as a variable for cancer outcomes in NC (Freeman et al., 2016). The researchers 
divided the state into nine geographic sections based on the location of Area Health 
Education Centers (AHECs) (Freeman et al., 2016).  AHECs are used to improve access 
to medical care and, for the purposes of the study, represented local healthcare 
infrastructure (Freeman et al., 2016; “The North Carolina AHEC Program,” n.d.).  The 
investigators found that survival outcomes among adult AML patients varied based on 
NC geographic regions, even after controlling for regional and patient demographic 
variables (Freeman et al., 2016).  It was later discovered that resources among the 
AHECs differ, with some having a greater number of cancer specialists than others, 
which may explain these disparities in survival outcomes (Freeman et al., 2016).   
This thesis study attempted to evaluate whether there are disparities in pediatric 
cancer survival outcomes in NC based on geography.  Other demographic characteristics 
were also examined, such as the patient’s race, ethnicity, sex, and metropolitan/non-
metropolitan classification of county of residence.  The hypothesis of the research was 
that a child’s cancer prognosis would vary based on the patient’s home location and the 
distance to the treating medical center.  To answer this question, a retrospective, single-
institution study of survival outcome based on distance to the University of North 
Carolina (UNC) Hospital was performed.  The University of North Carolina Institutional 
Review Board (IRB) approved this study.  
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METHODS 
 
Patients 
Eligibility was limited to patients who were 0-21 years of age at diagnosis with 
AML, acute lymphoblastic leukemia (ALL), CNS tumor(s), neuroblastoma, 
rhabdomyosarcoma, and Wilms tumor between the years 2000 and 2018, and who were 
NC residents and treated by the UNC Division of Pediatric Hematology Oncology (PHO) 
at the UNC Hospital.  These six cancer types were selected to reflect many of the more 
common diagnoses and to obtain a diverse sample based on factors such as tumor 
location or tissue type of origin in the body (Table 1), incidence rate, and mortality rate.  
All patients were first analyzed as a total group, and then the ALL cases were examined 
separately to serve as a case study.  
Table 1. Primary Site of Origin for Cancer Types Analyzed in Study.   
 
Diagnosis Primary Site of Origin 
Acute Lymphoblastic Leukemia Bone Marrow 
Acute Myeloid Leukemia Bone Marrow 
Central Nervous System 
Tumors 
Brain or Spinal Cord 
Neuroblastoma Sympathetic Nervous System 
Rhabdomyosarcoma Muscle  
Wilms Tumor Kidney 
This table shows the location of origin for pediatric cancer diagnoses that were analyzed 
in this study.  Data taken from the American Cancer Society (“Cancers that Develop in 
Children,” 2016). 
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Database 
Patients were identified using a Research Electronic Data Capture (REDCap) 
clinical database.  REDCap is a secure data platform maintained by the Translational and 
Clinical Sciences Institute (NC TraCS) at the University of North Carolina School of 
Medicine (UNC SOM) (Harris et al., 2009; “REDCap,” 2018).  Trained UNC Hospital 
employees enter patient information into REDCap, and data are uploaded from paper 
medical records stored in a secure location as well as from electronic medical records.  
The PHO at the UNC SOM utilizes a REDCap clinical database for internal feasibility, 
quality improvement, and the possibility of opening new clinical trials, but with the 
appropriate approvals the data can be used for research purposes.  After completion of a 
Data Use Agreement (DUA) between the PHO division chief, the “honest broker” for the 
PHO REDCap clinical database (a clinical research associate who is authorized to access 
and share the data) and the author, patient data were sent to the author for analysis.  
The patient data provided included date of birth, date of diagnosis, cancer type, 
metastatic status at diagnosis, disease presentation at the UNC Hospital (classified as 
initial diagnosis, relapse, or refractory disease), date of death (if applicable), last point of 
contact with UNC Hospital, and survival outcome.  Basic demographic information such 
as race, ethnicity, sex, street address and North Carolina county of residence was also 
included in the data provided.  
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Survival 
Subjects were considered to be alive when measuring survival outcome if they 
were not listed as deceased in REDCap as of February 1, 2019, and were then confirmed 
as alive if their point of last contact with the UNC Hospital was within one year of the 
study end date, defined as December 31, 2018.    
 
Definition of Home Location 
Patient home addresses were geocoded and the road-map distance was calculated 
for each patient from his or her location of residence to UNC Hospital (located in Chapel 
Hill, NC) using ArcGIS geographical software (ArcMap) (Esri, 2019).  ArcGIS software 
was also used to calculate the average drive times from each patient’s residence to the 
UNC Hospital.  Home locations were categorized as metropolitan or non-metropolitan 
based on NC county of residence using Rural-Urban Continuum Codes (RUCC) created 
by the United States Department of Agriculture (USDA).  The RUCC system classifies a 
county as metropolitan based on the population of its metro area (“RUCCs,” 2013).  NC 
has 100 counties, and of these counties, 46 are considered to be metropolitan based on 
RUCC criteria, and 54 are non-metropolitan (“RUCCs,” 2013) 
 
Statistics 
Descriptive statistics were used to summarize the data and compare survival 
outcome based on distance to UNC within each cancer type.  The percentage of deceased 
patients from each cancer type in this sample was calculated and compared to the US 
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national averages.  Average distances among each treatment group were also calculated.  
Demographic information regarding the study sample was summarized as well, including 
race, ethnicity, sex, and the metropolitan/non-metropolitan classification of a patient’s 
residence.  The REDCap clinical database separates race into seven different categories 
(African American, Asian, Caucasian, American Indian or Alaska Native, Pacific 
Islander, Other, and Unknown).  Due to a limited number of certain racial groups in this 
sample, race was divided into three categories (African American, White, and Other) for 
statistical analyses.  An individual who had selected multiple races was placed in the 
“Other” category.  Ethnicity was classified into two categories, Hispanic or non-Hispanic.  
R statistical software was used for all univariate and multivariate logistic regression 
calculations as well as box plot and histogram creation, with odds ratios used to compare 
data points (R Core Team, 2018).  All data shown to statisticians for help with analysis 
were de-identified to maintain the confidentiality of each patient.  
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RESULTS 
 
 
Patients 
A total of 1502 patients who met at least one of the exclusion criteria were 
identified by the honest broker.  Many of these patients had missing information, and data 
cleanup was performed with the following steps (Figure 2).  First, patients were sorted 
based on if they had a completed deceased category, listed as “yes” or “no,” which 
brought the sample down to 509 patients.  These patients were then sorted according to a 
completed primary diagnosis field, resulting in an updated sample size of 379 patients.  
Next, 6 patients were removed because they were not listed as NC residents.  Then, all 
alive patients were confirmed as alive if they had contact with the UNC Hospital within 
the last year of the study date (i.e. between 12/31/17 and 12/31/18), and 28 patients were 
removed because a last point of contact fell outside the defined time period.  Finally, 
from the 345 patients remaining, 36 were removed because of incomplete data regarding 
race or ethnicity.  After data cleanup was completed, a total of 309 patients remained 
with the following diagnoses: 184 ALL cases, 21 AML cases, 35 CNS tumor cases, 27 
neuroblastoma cases, 21 rhabdomyosarcoma cases, and 21 Wilms tumor cases (Table 2).  
All 309 patients were analyzed as a total group, and then the 184 ALL cases were 
examined as a case study.  
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Figure 2.  Flowchart for the sample selection process.  This figure shows how data 
cleanup was performed.  NC = North Carolina.  
 
The entire cohort was composed of 181 (58.6%) males and 128 (41.4%) females 
(Table 3).  This follows the general trend that males have a higher incidence of pediatric 
cancer than females (Dorak & Karpuzoglu, 2012).  The ALL cases had a similar 
breakdown on the basis of sex as the entire cohort, with 113 (61.4%) male cases and 71 
(38.6%) female cases.  AML, rhabdomyosarcoma, and Wilms tumor also followed this 
Total	Patients	Analyzed	=	309		
Completed	Race/Ethnicity	309	Patients	
Confirmed	Alive	345	Patients	
NC	Residents	373	Patients	
Completed	Primary	Diagnosis	379	Patients	
Completed	Alive/Deceased	Status	509	Patients		
Honest	Broker	Patient	Identification		1502	Patients	
Patient	Eligibility	Criteria	Created	
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trend, each having approximately a 60% male to 40% female comparison.  CNS and 
neuroblastoma cases had roughly the same number of males and females in each group.   
The majority of subjects were classified as White race (61.2%), with African 
Americans accounting for 16.5% and the “Other” race category accounting for the 
remaining 22.3% of the sample (Table 3).  For all cancer types, the most common race 
was White, with African Americans and “Other” races having similar numbers of people 
in each cancer group relative to each other.  One exception to this trend was in the ALL 
group, in which almost twice as many individuals identified as an “Other” race category 
compared to African Americans.   
For patient ethnicity, non-Hispanics made up the majority of the sample (84.1%), 
and Hispanics classified as 15.9% of the cohort (Table 3).  For all cancer types, non-
Hispanic individuals made up the majority of each group.    
 
Survival 
Out of the 309 eligible patients, ALL accounted for over half (59.5%) of the 
diagnoses, CNS tumors for 11.3% of diagnoses, AML for 6.8%, neuroblastoma for 8.7%, 
rhabdomyosarcoma for 6.8%, and Wilms tumor for 6.8% (Figure 3).  ALL cases had the 
lowest mortality rate, with only 4.9% succumbing to their disease (Table 2).  
Rhabdomyosarcoma patients had the highest percentage deceased, with a mortality rate 
of 33.3%. 
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Table 2. Cancer Types and Mortality Rates of Sample. 
Cancer Type Number of 
Patients 
Alive  
(%) 
Deceased  
(%) 
All cancers  309 269 
(85.1%) 
40 
(14.9%) 
    
ALL 184 175 
(95.1%) 
9  
(4.9%) 
AML 21 16 
(76.2%) 
5 
(23.8%) 
CNS 35 24 
(68.6%) 
11 
(31.4%) 
Neuroblastoma 27 21 
(87.8%) 
6 
(22.2%) 
Rhabdomyosarcoma 21 14 
(66.7%) 
7 
(33.3%) 
Wilms Tumor 21 19 
(90.5%) 
2 
(9.5%) 
This table shows the number of diagnoses for each cancer type in the sample and also 
summarizes the number of individuals who were alive or deceased.  ALL= acute 
lymphoblastic leukemia, AML= acute myeloid leukemia, CNS= central nervous system 
tumors. 
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Figure 3. Percentage of each cancer type in sample.  This figure shows the number of 
each cancer type represented in the sample analyzed.  ALL= acute lymphoblastic 
leukemia, AML= acute myeloid leukemia, CNS= central nervous system tumors. 
 
 
Table 3.  Summary of Demographic Characteristics in Sample.   
 
Cancer type Male Female White African 
Americans 
Other Non-
Hispanic 
Hispanic 
All cancers  181 128 189  51 69 260 49 
        
ALL 113 71 116 26 42 152 32 
AML 13 8 12 4 5 16 5 
CNS 18 17 20 9 6 34 1 
Neuroblastoma 13 14 17 3 7 24 3 
Rhabdomyosarcoma 12 9 13 5 3 17 4 
Wilms Tumor 12 9 11 4 6 17 4 
This table shows the demographic information among each cancer type, including sex, 
race, and ethnicity.  ALL= acute lymphoblastic leukemia, AML= acute myeloid 
leukemia, CNS= central nervous system tumors. 
 
 
 
 
 
Cancer	Types	in	Sample	ALL	AML	CNS	Neuroblastoma	Rhabdomyosarcoma	Wilms	Tumor	
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Home Location:  
For all cancer types, patients lived an average of 67 miles away from the UNC 
Hospital (Table 4).  Distance was further compared between those who were alive versus 
those who were deceased at the time of the study for each cancer type (Figure 4).  For the 
entire group, patients listed as “alive” lived closer to the UNC Hospital than the deceased 
patients, although this varied when separated by cancer type.  Patients diagnosed with 
ALL, AML, rhabdomyosarcoma, and Wilms tumor all followed this trend.  Conversely, 
on average, patients with a CNS tumor diagnosis who were considered alive lived 40+ 
miles farther from the UNC Hospital compared to those who were deceased.  
Neuroblastoma patients had similar distance values between groups (Figure 6).  Distance 
to the UNC Hospital was similar across both deceased and alive racial groups (Figure 5).  
 
Table 4.  Average Distance to the UNC Hospital and Alive versus Deceased Status for 
Cancer Types in Sample 
 
Cancer Type Average 
Distance to 
UNC 
Hospital 
(miles)  
Average 
Distance to 
UNC Hospital 
(miles) Among 
Alive  
Average 
Distance to 
UNC Hospital 
(miles) Among 
Deceased 
All cancers  66.78 65.81 73.30 
    
ALL 64.21 63.73 73.60 
AML 61.89 55.95 80.91 
CNS 83.36 96.40 54.91 
Neuroblastoma 69.48 69.54 69.26 
Rhabdomyosarcoma 66.42 53.08 93.11 
Wilms Tumor 63.37 59.85 96.83 
This table shows how far from the UNC Hospital patients in each cancer group resided, 
along with the distances among those who are alive versus deceased for comparison.  
UNC= University of North Carolina, ALL= acute lymphoblastic leukemia, AML= acute 
myeloid leukemia, CNS= central nervous system tumors. 
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Figure 4. Histogram comparing distance to UNC Hospital between those who are alive 
versus deceased in sample.  This figure shows the distance distributions for those patients 
who are alive (red) versus those who are deceased (turquoise) for all cancer types in the 
sample.  Legend: 0=alive where N = 269, 1 = deceased where N = 40.  UNC = University 
of North Carolina.  
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Figure 5.  Comparison of distance to the UNC Hospital and alive (red) or deceased 
(turquoise) status for race in the sample.  This box plot shows how the median distance to 
the UNC Hospital among the alive and deceased groups was similar, represented by the 
middle line in each box.  NBlack=51, NOther=69 Nwhite= 189. 
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Figure 6. Comparison of distance to the UNC Hospital and alive versus deceased status 
for each cancer type in the sample.  This box plot shows how distance (miles) to the UNC 
Hospital varied between each cancer group, with alive patients living closer to the UNC 
Hospital among ALL, AML, rhabdomyosarcoma, and Wilms tumor patients.  CNS 
patients who were deceased lived closer to the UNC Hospital compared to those who 
were alive, and data from neuroblastoma patients was similar among each group.  UNC= 
University of North Carolina, ALL= acute lymphoblastic leukemia, AML= acute myeloid 
leukemia, CNS= central nervous system tumors.  Legend: 0=alive (red), 1=deceased 
(turquoise).  The number of alive and deceased patients in each group can be found in 
Table 2.  
 
 
Over three-quarters of the sample resided in a metropolitan county, with 
neuroblastoma, rhabdomyosarcoma, and Wilms tumor patients primarily living in 
metropolitan areas (Table 5).  Overall, a higher percentage of non-metropolitan county 
patients were deceased (17.1% non-metropolitan patients were deceased compared to 
11.7% metropolitan patients).  Children diagnosed with ALL, AML, neuroblastoma, and 
rhabdomyosarcoma followed this trend.  More patients living in metropolitan areas with 
	18 
CNS and Wilms tumor were deceased, with no patients with Wilms tumor living in non-
metropolitan areas classified as deceased from the sample. 
 
Table 5.  Metropolitan Classification and Alive/Deceased Status for Cancer Types in 
Sample 
 
Cancer Type Metro 
(%) 
Non-
Metro 
(%) 
Percent 
Deceased 
Metro 
Percent 
Deceased 
Non-
Metro 
All cancers  239 
(77.3%) 
70 
(22.7%) 
11.7% 17.1% 
     
ALL 137 
(74.5%) 
47 
(25.5%) 
2.92% 10.6% 
AML 16 
(76.2%) 
5 
(23.8%) 
18.8% 40.0% 
CNS 26 
(74.3%) 
9 
(25.7%) 
34.6% 22.2% 
Neuroblastoma 24 
(88.9%) 
3 
(11.1%) 
20.8% 33.3% 
Rhabdomyosarcoma 17 
(81%) 
4 
(19%) 
29.4% 50% 
Wilms Tumor 19 
(90.5%) 
2 
(9.5%) 
10.5% 0.0% 
This table shows the number of patients in each cancer type that live in either 
metropolitan or non-metropolitan counties.  It can be seen that most patients resided in 
metropolitan areas. ALL= acute lymphoblastic leukemia, AML= acute myeloid leukemia, 
CNS= central nervous system tumors.   N = 309. 
 
Statistical Analyses- Total Group 
As shown in Table 6, after univariate and multivariate regression analyses, it was 
found that distance did not have a statistically significant impact on survival outcome 
(p=0.831).  Although distance did not influence survival outcome, patients living in non-
metropolitan areas had a lower survival outcome when compared to patients residing in 
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metropolitan regions (p=0.060).  Also, patients who were African Americans and “Other” 
races had a lower survival outcome when compared to Whites (p=0.0020, p=0.016, 
respectively).  Statistical significance was defined as a p < 0.05.   
 
Table 6. Univariate and Multivariate Regression Analyses for Sample.  
 Crude 
OR 
CI 
(95%) 
p-value  Adjusted 
OR 
CI 
(95%) 
p-value 
Distance 1.003 0.9962, 
1.0094 
0.548  1.001 0.9922, 
1.0088 
0.831 
ALL Ref Ref Ref  Ref Ref Ref 
AML 6.076 1.701, 
19.933 
0.0034  6.785 1.811, 
23.643 
0.0029 
CNS 8.912 3.363, 
24.335 
0.000012  8.340 2.952, 
24.431 
0.0000711 
Neuroblastoma 5.556 1.717, 
17.023 
0.0029  6.788 1.930, 
23.124 
0.00215 
Rhabdomyosarcoma 9.722 3.076, 
30.290 
0.000077  11.795 3.514, 
39.700 
0.0000534 
Wilms Tumor 2.046 0.298, 
8.6976 
0.38  2.193 0.308, 
9.900 
0.352 
Metro Ref Ref Ref  Ref Ref Ref 
Non-Metro 1.559 0.724, 
3.193 
0.237  2.325 0.953, 
5.623 
0.0602 
Male Ref Ref Ref  Ref Ref Ref 
Female 0.935 0.467, 
1.826 
0.845  0.648 0.291, 
1.388 
0.273 
White Ref Ref Ref  Ref Ref Ref 
African-American 3.699 1.624, 
8.338 
0.0016  4.189 1.679, 
10.507 
0.00204 
Other 2.051 0.880, 
4.638 
0.087  3.990 1.264, 
12.241 
0.0161 
Non-Hispanic Ref Ref Ref  Ref Ref Ref 
Hispanic 0.731 0.241, 
1.818 
0.535  0.388 0.0900, 
1.483 
0.18 
This table presents a summary of the logistic regression calculations performed.  
Columns 2-4 show crude analyses, where only one variable was compared to survival 
outcome.  Columns 6-8 show adjusted analyses, where multiple variables were 
controlled.  OR= odds ratio, CI= confidence interval, Ref= reference group, UNC= 
University of North Carolina, ALL= acute lymphoblastic leukemia, AML= acute myeloid 
leukemia, CNS= central nervous system tumors.  
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Crude regression analysis generated an odds ratio (OR) of 1.003 when calculating 
odds of death as a function of distance (Table 6).  After adjusting for sex, race, ethnicity, 
and the metropolitan/non-metropolitan classification of the patient’s county of residence, 
the analysis produced an odds ratio of 1.001 when calculating odds of death as a function 
of distance (p=0.831, or not statistically significant).  In the adjusted regression model, it 
was found that those living in non-metropolitan areas were more likely to have a lower 
survival outcome than individuals living in metropolitan areas (p = 0.060).  In addition, 
adjusted analyses also showed that African Americans along with “Other” minority races 
had a lower survival outcome when compared to Whites (p = 0.002, p=0.016 
respectively).  Males and females were found to have similar odds of death, and the 
difference in odds ratios with death as a function of sex was not statistically significant 
(p=0.273).  Hispanic versus non-Hispanic patients were also found to have similar odds 
of death, and the difference in odds ratios regarding ethnicity was not statistically 
significant (p=0.180).  
The odds ratios examining odds of death as a function of cancer type were also 
compared.  ALL was selected to be the reference group because this cancer type had the 
highest sample size.  High odds ratio values and wide confidence intervals were produced 
because of the low mortality rate of patients with ALL included in this sample compared 
to the other malignancies, particularly rhabdomyosarcoma.  All other cancer types except 
for Wilms tumor were found to have statistically significant higher odds of death 
(p<0.05) when compared to the ALL cases.  
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Acute Lymphoblastic Leukemia Case Study 
After all patients in the group were studied as a whole, patients with ALL were 
further examined.  Individuals with this cancer type were chosen for additional analysis 
for a number of reasons.  First, ALL is the most common pediatric cancer diagnosis in the 
US (“Pediatric Cancers,” 2012).  Second, as stated previously, out of the 309 total cases, 
184 were ALL patients, which made up 59.5% of the sample (Figure 7).  These patients 
were more thoroughly analyzed to determine to what extent they influenced the overall 
data set and statistical calculations.  Finally, this 184 person sample was a sufficient size 
to perform regression tests and other statistical measures.  The other cancer groups had 
relatively small sample sizes ranging in number from 21 to 35 patients in the AML, CNS, 
neuroblastoma, rhabdomyosarcoma, and Wilms tumor groups.    
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Figure 7.  Flowchart for sample selection process in ALL case study.  This figure 
shows the steps taken to sort all patients and create the ALL case study group.  
ALL= acute lymphoblastic leukemia, NC= North Carolina. 
  
The ALL sample had a very low mortality rate compared to the other cancer 
groups in this study (Table 7).  The ALL sample had a 5% death rate compared to a 25% 
death rate in the other five cancer groups.  Both groups had a higher number of males 
than females, with 61.4% males to 38.6% females in the ALL sample, and 54.6% males 
to 45.6% females in the other cancer groups.  The racial breakdown was also similar 
Total	Patients	Analyzed	in	ALL	case	study	=	184		
ALL	Cases	184	Patients	
Completed	Race/Ethnicity	309	Patients	
Confirmed	Alive	345	Patients	
NC	Residents	373	Patients	
Completed	Primary	Diagnosis	379	Patients	
Completed	Alive/Deceased	Status	509	Patients		
Honest	Broker	Patient	Identification		1502	Patients	
Patient	Eligibility	Criteria	Created	
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between both groups, with the majority of patients identifying as White.  There were a 
higher percentage of African Americans in the other five cancer groups (21.6%) 
compared to ALL (14.1%).  Furthermore, “Other” races comprised a relatively equal 
amount of the sample for both groups, with 22.8% in the ALL sample and 20.0% in the 
other five cancer groups (Figure 9).  Regarding ethnicity, the Hispanic/non-Hispanic 
classification was also similar between both groups, with non-Hispanic patients 
comprising the majority of the sample (82.6% in the ALL group and 86.4% in the other 
five cancer groups).  
Table 7. Demographic Comparison of ALL group and Rest of Cohort. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This table compares the demographic characteristics between the ALL case study and the 
other five cancer groups.  NALL= 184, NRest= 125. ALL= acute lymphoblasatic leukemia. 
 
Variable Number in 
ALL 
sample 
Percent of 
ALL Sample 
 Number in 
Other Five 
Cancer 
Groups 
Percent of 
Other Five 
Cancer 
Groups 
      
Alive 175 95.1%  94 75.2% 
Deceased 9 4.9%  31 24.8% 
      
Male 113 61.4%  68 54.4% 
Female 71 38.6%  57 45.6% 
      
White 116 63.1%  73 58.4% 
African 
American 
26 14.1%  27 21.6% 
Other 42 22.8%  25 20.0% 
      
Non-Hispanic 152 82.6%  108 86.4% 
Hispanic 32 17.4%  17 13.6% 
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The majority of patients in each group (74.5% in ALL, 81.6% in the other five 
cancer groups) lived in a metropolitan county at the time of this study (Table 8).  
However, there were notable differences in the mortality rate among metropolitan versus 
non-metropolitan counties, with only a 2.92% death rate among metropolitan patients in 
the ALL sample compared to a 23.5% death rate among patients in the other five cancer 
groups living in metropolitan areas.  Furthermore, ALL patients living in non-
metropolitan areas were found to have a 10.6% death rate compared to a 30.4% death rate 
for non-metropolitan patients in the other cancer groups.  Patients in each sample lived 
approximately the same distance from the UNC Hospital, with subjects in the other five 
cancer groups living slightly farther away (71 miles away compared to 64 miles in the 
ALL group).  The majority of ALL cases who were alive lived within 100 miles of the 
UNC Hospital (Figure 8).  Of note, deceased patients from each group lived 73-74 miles 
away from the UNC Hospital.  Those who were deceased and classified as an “Other” 
race were found to live farther away from the UNC Hospital compared to the African 
American and White racial groups in the sample (Figure 9). 
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Table 8. Metropolitan Classification and Average Distance to UNC Hospital for the ALL 
Group and the Rest of the Cohort.  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This table compares the ALL sample (N=184) and the rest of the cohort (N=125) based 
on metropolitan classification of patient NC county of residence and average distance to 
the UNC Hospital.  UNC=University of North Carolina, ALL= acute lymphoblastic 
leukemia.  
 
 
 
 
 
 
 
 
Variable ALL Sample  Other Five Cancer Groups  
   
Metropolitan 137 102 
Non-Metropolitan 47 23 
Percent Deceased 
Metropolitan 
2.92% 23.5% 
Percent Deceased  
Non-Metropolitan 
10.6% 30.4% 
   
Average Distance to 
UNC Hospital (miles) 
64.2 70.6 
Average Distance to 
UNC Hospital (miles) 
Among Alive 
63.7 69.7 
Average Distance to 
UNC Hospital (miles) 
Among Deceased  
73.6 73.2 
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Figure 8. Histogram comparing distance to the UNC Hospital in the ALL case study.  
This figure shows the distributions for those who are alive (N=175) versus those who are 
deceased (N=9) for ALL cases in the sample. UNC= University of North Carolina, ALL= 
acute lymphoblastic leukemia.  Legend: 0=alive (red), 1=deceased (turquoise). 
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Figure 9. Comparison of distance to the UNC Hospital and alive versus deceased status 
for race in the ALL case study.  This box plot shows how distance to the UNC Hospital 
varies between racial groups.  NBlack=26, NOther= 42, NWhite=116.  UNC= University of 
North Carolina, ALL= acute lymphoblastic leukemia.  Legend: 0 = alive (red), 1 = 
deceased (turquoise). 
 
Statistical Analyses- ALL Case Study 
Univariate and multivariate regression analyses were performed on ALL cases to 
see to what extent non-medical factors influenced survival (Table 9).  It was determined 
that distance did not have a statistically significant impact on survival outcome 
(p=0.817).  However, patients living in non-metropolitan counties had a statistically 
significant lower survival outcome when compared to patients in metropolitan counties 
(p=0.022).  In addition, African Americans had a statistically significant lower survival 
outcomes when compared to Whites (p=0.006).  Again, statistical significance was 
defined as a p < 0.05.   
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Table 9. Univariate and Multivariate Regression Analyses for ALL Case Study 
Variable Crude 
OR 
CI 
(95%) 
p-
value 
 Adjusted 
OR 
CI (95%) p-
value 
Distance 1.004 0.990, 
1.015 
0.548  1.002 0.984, 
1.012 
0.817 
Metro Ref Ref Ref  Ref Ref Ref 
Non-
Metro 
3.958 1.004, 
16.636 
0.047  6.283 1.354, 
34.424 
0.022 
Male Ref Ref Ref  Ref Ref Ref 
Female 0.787 0.162, 
3.087 
0.74  0.629 0.106, 
2.900 
0.570 
White Ref Ref Ref  Ref Ref Ref 
African-
American 
6.848 1.418, 
36.841 
0.016  11.172 2.059, 
72.823 
0.006 
Other 1.883 0.242, 
11.761 
0.497  5.278 0.353, 
52.297 
0.169 
Non-
Hispanic 
Ref Ref Ref  Ref Ref Ref 
Hispanic 0.581 0.031, 
3.333 
0.614  0.201 0.00756, 
3.014 
0.251 
This table presents a summary of the logistic regression calculations performed.  
Columns 2-4 show crude analyses, where only one variable was compared to survival 
outcome.  Columns 6-8 show adjusted analyses, where multiple variables were 
controlled.  ALL= acute lymphoblastic leukemia, OR= odds ratio, CI= confidence 
interval, Ref= reference group. (p<0.05 is considered statistically significant, NALL=184, 
NRest=125). 
 
Crude regression analysis generated an odds ratio (OR) of 1.004 when calculating 
odds of death as a function of distance for the ALL group.  After adjusting for sex, race, 
ethnicity, and the metropolitan/non-metropolitan classification of the patient’s county of 
residence, the analysis produced an odds ratio of 1.002 when calculating odds of death as 
a function of distance.  In the adjusted regression model, it was found that those living in 
non-metropolitan areas were more likely to have a lower survival outcome than 
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individuals living in metropolitan areas (p = 0.022).  In addition, adjusted analysis also 
showed that African Americans had a lower survival outcome when compared to Whites 
(p = 0.006).  Patients in the “Other” racial group were not found to have a statistically 
significant lower survival outcome when compared to Whites (p=0.169).  This result 
differed from the statistically significant higher odds of death for “Other” races compared 
with Whites, which was calculated when considering the entire sample group (Table 6).  
Males and females were found to have similar odds of death, and the difference in 
odds ratios for death as a function of sex was not statistically significant (p=0.570).  
Hispanic versus non-Hispanic patients were also found to have similar odds of death, and 
the difference in odds ratios regarding ethnicity was not statistically significant (p= 
0.251). 
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DISCUSSION 	
This single-institution retrospective study described pediatric cancer survival 
outcome data across North Carolina for patients treated at the University of North 
Carolina Hospital from 2000 to 2018.  The results suggest that for residents with one of 
six diagnoses (ALL, AML, CNS tumors, neuroblastoma, rhabdomyosarcoma, and Wilms 
tumor), distance to the UNC Hospital did not impact survival outcome.  However, other 
non-medical factors such as metropolitan/non-metropolitan classification of a patient’s 
county of residence and race were linked to survival disparities.  
It should be noted that there were significant limitations with the data.  First, a 
majority of the patients examined were at some point enrolled in a research study rather 
than treated according to a standard of care.  Therefore, the sample does not fully 
represent the patient population at the UNC Hospital due a bias in the patients analyzed.  
Another limitation of this project was the small sample size.  This problem was likely 
caused by the eligibility for the database (as previously noted), the retrospective nature of 
the study, the relative rarity of pediatric cancer in the general population, and missing 
data.  The small sample size restricted the extent of statistical analyses which could be 
performed on individual cancer types.  Unfortunately, time-related data (such as date of 
diagnosis, date off treatment, and date of death) were not available for all patients and 
were therefore not analyzed in this study.   
The mortality rates of each cancer type in this sample were similar to the US 
national averages (Table 10), although there were some differences (“SEER 5-Year 
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Relative Survival,” 2014).  The ALL group in this sample had approximately half the 
mortality rate compared to the U.S. national average (4.9% versus 10.8%) (“SEER 5-
Year Relative Survival,” 2014).  The AML group in this sample also had a lower 
mortality rate compared to the US national average (23.8% versus 32.9%) (“SEER 5-
Year Relative Survival,” 2014).  The CNS mortality rate of this sample was higher than 
the US national average (31.4% versus 24.5%), although the national value included 
other nervous system tumors (“SEER 5-Year Relative Survival,” 2014).  The mortality 
rate for rhabdomyosarcoma in this sample looks much higher compared to the SEER 
data.  However, the SEER group included patients with other soft-tissue tumor diagnoses 
in addition to rhabdomyosarcoma, which likely impacted the data (“SEER 5-Year 
Relative Survival,” 2014).  In addition, the mortality rates among neuroblastoma and 
Wilms Tumor patients were similar between the sample analyzed and the US national 
average (“SEER 5-Year Relative Survival,” 2014). 
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Table 10. Comparison of Mortality Rates of Sample with US National Averages. 
 
Cancer Type Sample Percent 
Deceased 
U.S. Average 
Percent Deceased 
ALL 4.9% 10.8% 
AML 23.8% 32.9% 
CNS 31.4% 24.5%* 
Neuroblastoma 22.2% 24.8% 
Rhabdomyosarcoma 33.3% 19.9%** 
Wilms Tumor 9.52% 9.6% 
This table contains data based on SEER 5-year survival rates between 2008 and 2014 for 
children aged 0-19 years old in the United States.  UNC= University of North Carolina, 
ALL= acute lymphoblastic leukemia, AML= acute myeloid leukemia, CNS= central 
nervous system tumors, US= United States.  Data taken from  (“SEER 5-Year Relative 
Survival,” 2014). 
*Data based on brain and other nervous system malignancies. 
**Data based on soft-tissue malignancies.  
 
 
Although this study found there is no statistically significant relationship between 
distance and survival outcome for NC pediatric cancer patients, it is possible that the 
limitations in the database did not enable the ability to fully appreciate this effect.  In 
addition, it is still very likely those patients who live far away from the UNC Hospital 
may face significant transportation burdens.  This may particularly apply to patients who 
live in the easternmost or westernmost portions of NC, where travel distances to seek 
treatment are the furthest.  The UNC Hospital, which was used as the treatment center of 
interest, is situated in the approximate middle of state, located in Chapel Hill, NC.  This 
institution is a state-supported hospital system that operates as a safety-net institution for 
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the region (UNC Healthcare “Vision and Values,” 2019).  A safety-net hospital provides 
healthcare for “vulnerable populations,” such as those who are uninsured or on Medicaid, 
and the UNC Hospital operates with the mission of improving the health of all North 
Carolinians (“Definition of Safety Net Hospitals,” 2013; “Vision and Values,” 2019).  
North Carolina has a population of over 10 million people and is a relatively large 
state with a land area of 48,618 square miles, including diverse geographic regions 
among its 100 counties with the Appalachian Mountains in the west and the Atlantic 
Ocean in the east (“Quick Facts NC,” 2018).  The population breakdown by county and 
the racial statistics for the state are summarized in Tables 11 and 12, respectively.  For 
reference, 4834 children were diagnosed with cancer in NC between 2003 and 2014 
(Siegel et al., 2018).  In 2014 specifically, there were 373 new cases of pediatric cancer 
among children and adolescents aged 0-19 years old, with 61 total deaths in NC (Siegel et 
al., 2018). 
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Table 11. North Carolina Population by County Based on Estimates from July 2017.  
 
Number of NC Counties Population   
17 <20,000 
22 20,000-40,000 
15 40,000-60,000 
11 60,000-80,000 
8 80,000-100,000 
9 100,000-150,000 
7 150,000-200,000 
9 200,000-600,000 
2 >1,000,000 
This table shows the population of NC counties based on population groupings.  Data 
taken from NC Office of State Budget and Management 2017 (“2017 Certified County 
Population Estimates,” 2018).  NC= North Carolina. 
 
 
Table 12.  Racial Breakdown of North Carolina as of July 2018.  
 
Race Percent of Population 
White 70.8% 
African American 22.2% 
American Indian or Alaska 
Native 
1.60% 
Asian 3.10% 
Native Hawaiian or Pacific 
Islander  
0.10% 
Two or More Races 2.20% 
This table shows the breakdown of racial groups for the North Carolina population.  Data 
taken from US Census Bureau. (“Quick Facts NC,” 2018). 
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In this study sample, approximately 19% of patients lived over 100 miles away 
from the UNC Hospital (58 of the 309 total patients), a distance that can pose a 
significant burden over several months or years of treatment.  Based on the raw data, it 
appears that those patients who were deceased lived, on average, much further away from 
the UNC Hospital compared to those patients who were alive.  However, likely due to the 
effectiveness of current treatments and relatively low mortality rates across many 
pediatric cancer types, the deceased outcome group had a much lower sample size than 
the alive outcome groups, and individuals who lived far away from the UNC Hospital in 
the deceased group noticeably impacted the averages.  Therefore, when determining if 
there was an association between distance to the UNC Hospital and survival outcome, 
odds ratios rather than raw averages were used. 
Some studies suggest that those who live in rural or remote areas that must travel 
significant distances for care feel an even greater overall burden compared to those with 
short travel times (Farquhar et al., 2018; Fluchel et al., 2014).  For example, in one study, 
researchers surveyed over 300 patients treated at Primary Children’s Hospital in Salt 
Lake City, Utah, to investigate the impact pediatric cancer can have on a family (Fluchel 
et al., 2014).  The results of the survey indicated that rural responders had a higher travel 
expenses and more missed days of work/school compared to those living in non-rural 
areas (Fluchel et al., 2014).  Another study, conducted in NC, found that among low-
income adults with head and neck squamous cell carcinoma, individuals with longer 
travel times to a healthcare provider had a higher risk for a late-stage diagnosis compared 
to those who live close by (Farquhar et al., 2018).  These conclusions correlate with the 
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results of this study, in which patients living in non-metropolitan areas had higher odds of 
succumbing to their cancer compared to patients in metropolitan regions.  
Patients who live significant distances from their primary treatment center may 
face transportation barriers that prevent them from receiving treatment (Syed, Gerber, & 
Sharp, 2013).  Although relatively little research has been done in this area, the results 
have shown that those facing transportation barriers may limited access to healthcare, 
which can lead to missed appointments and lower survival outcomes (Syed, Gerber, & 
Sharp, 2013).  One obvious difference between child and adult patients living in an area 
without easily accessible public transportation is that children are particularly reliant on 
someone physically driving them to the treatment center because they are too young for a 
driver’s license. 
Distance from treatment center is one of many of the different non-medical 
factors that can influence a pediatric cancer prognosis, and reasons for survival disparities 
are likely diverse, including elements such as race, ethnicity, sex, and socioeconomic 
status. One review noted that even though pediatric cancer survival outcomes have been 
improving over the past several decades, survival disparities still exist between racial 
groups (Bhatia, 2011).  These observations are reflected in the results of this study, in 
which African Americans had a higher mortality rate compared to Whites in the sample 
group.  Although many of these variables are connected, relatively few papers have 
explicitly analyzed how distance to care impacts pediatric cancer survival outcome in NC 
as in this study.    
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Incidence of pediatric cancers can also vary based on non-medical factors.  In one 
study, the Centers for Disease Control and Prevention (CDC) examined the incidence of 
pediatric cancer from 2003 to 2014 as a function of geographic location (according to 
census region) within the US (Siegel et al., 2018).  The investigators also analyzed 
variables such as gender, age, race and ethnicity (Siegel et al., 2018).  They found that 
pediatric cancer incidence was the highest in the Northeast part of the country, including 
New Jersey, Pennsylvania, New York and New England (“Geography Regions,” 2015; 
Siegel et al., 2018).  In addition, the CDC report also observed that pediatric cancer 
incidence was highest in males, children 0-4 and 15-19 years old, Whites, and 
metropolitan areas with a population of over one million people (Siegel et al., 2018).  A 
similar study took place on a smaller scale, where a research team investigated pediatric 
cancer incidence in Delaware between the years 2004 and 2014, in which they found that 
incidence varied based on zip code and also noted differences between racial groups 
(Holmes, Vandenberg, McClarin, & Dabney, 2015).  The authors of both studies offered 
possible explanations on why these disparities in pediatric cancer exist, citing 
environmental factors, genetic differences between populations, parental lifestyle and/or 
parental occupation (Holmes. et al., 2015; Siegel et al., 2018).  
Although pediatric cancer diagnoses are rare, further research is needed to better 
understand and treat these patients due to the severity of this group of diseases, which in 
addition to physical harm can also cause psychological problems, including depression 
and anxiety (Abrams, Hazen, & Penson, 2007; Marcus 2012).  The major factors that 
determine how a child processes a cancer diagnosis are his or her age and stage of 
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cognitive development (Marcus, 2012).  One group in which the psychological impact of 
a cancer diagnosis can be the most severe is among adolescents (Abrams et al., 2007).  
Normally, adolescence is a time where an individual seeks to become more independent 
and wants to create his or her own identity (Abrams et al., 2007).  However, due to the 
severity of cancer and the harmful effects of treatments, many teens are required to rely 
heavily on their parents or others for help with everyday tasks, such as driving (Abrams 
et al., 2007).  This limitation in autonomy can lead to problems with relationships and 
unhealthy coping mechanisms, including decreased compliance with medications 
(Abrams et al., 2007). 
The psychological impact of a pediatric cancer diagnosis can also extend to the 
child’s family.  Interestingly, it has been shown that parents are more likely to develop 
post-traumatic stress disorder (PTSD) or symptoms of PTSD compared to the pediatric 
patient (Kazak et al., 2004).  Among pediatric cancer survivors, higher rates of PTSD are 
found in patients who were diagnosed and underwent treatment at an older age, likely due 
to the fact that younger children do not remember the experience as well (Kazak et al., 
2004).  Siblings of the patient may also develop mental health problems related to a 
cancer diagnosis (Alderfer & Hodges, 2010). One study found that, according to parent 
reports, siblings were shown to express anxiety, withdrawal, and aggressive behaviors 
(Alderfer & Hodges, 2010).  
 Furthermore, pediatric cancer care can place a significant financial burden on both 
the family as well as the patient later on in life (Abrams et al., 2007; Alderfer & Hodges, 
2010; Kazak et al., 2004; Warner, Kirchoff, Nam, & Fluchel, 2014).  Hospitalization 
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costs for pediatric cancer can be very expensive, likely due to the unique challenges of 
these diseases which often require high-end medications and complex procedures (Price, 
Stranges, & Elixhauser, 2012).  One study, conducted at the Primary Children’s Hospital 
in Salt Lake City, Utah, surveyed over 250 families and found that a major source of 
financial strain came from unexpected hospitalizations, particularly when they occurred 
between 1 and 5 years after diagnosis (Warner et al., 2014).  Additionally, even if the 
cancer is cured, many survivors must continually seek follow-up care for the rest of their 
lives due to the harmful effects of certain treatments and increased risk for future 
malignancies (Huang et al., 2019).  Among pediatric cancer survivors, financial hardship 
has also been associated with a lower quality of life (Huang et al., 2019).  
 Parents of children with cancer have cited that non-medical costs related to 
seeking treatment can cause significant financial strain, largely because these expenses 
are usually not covered by their insurance (Lansky et al., 1979).  Examples of these costs 
include transportation and lodging expenses (Lansky et al., 1979).  One study, after 
surveying 70 families with children undergoing cancer treatment at the University of 
Kansas Medical Center, found that the greatest non-medical expenses were associated 
with inpatient hospitalizations and long travel distances (Lansky et al., 1979).  Other 
studies have attributed feelings of financial distress among parents to disruptions in work 
schedules (Bona et al., 2014; Lansky et al., 1979; Warner et al., 2014).  For example, 
after surveying over 250 families with a child that had pediatric cancer, a study reported 
that one-third of caregivers reported having to either change their work or quit their job 
entirely (Warner et al., 2014).  Another study, which only included parents of children 
	40 
diagnosed with advanced cancer, found that over 94% of parents reported some kind of 
work disruption (Bona et al., 2014).  
The financial strains of pediatric cancer can impact families across all income 
levels (Bona et al., 2014).  However, it has been shown that families with a lower income 
or who live in rural areas experience a greater financial burden (Bona et al., 2014; Lansky 
et al., 1979; Warner et al., 2014).  Unfortunately, the monetary impact of pediatric cancer 
care can be insurmountable, threatening the family with bankruptcy (Lansky et al., 1979).  
In other cases, even if the family manages to successfully pay off the medical expenses, 
both the parents and siblings of the pediatric cancer patient may be deprived of goods as 
the majority of family funds are spent on medical bills (Lansky et al., 1979).  Additional 
research is required to further examine the impact of financial burdens caused by a 
pediatric cancer diagnosis along with solutions to this serious problem, where one study 
has noted that working with a financial advisor and possibly a social worker can help 
lessen its economic impact (Warner et al., 2014). 
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Figure 10. Potential non-medical influences on pediatric cancer survival.  This figure 
shows how a variety of non-medical factors can impact a pediatric cancer prognosis. SES 
= socioeconomic status.  
 
Other limitations with this project include the fact that patient compliance to 
treatment plan and medications were unavailable. Socioeconomic status (SES) was also 
not recorded, and instead distance to the UNC Hospital along with the classification of a 
patient’s NC county of residence as metropolitan/non-metropolitan were used as 
surrogate markers for SES.  SES data would have been particularly useful for this project 
because this information could have helped predict other non-medical factors pertinent to 
this research question, such as car ownership.  However, considering this was a 
retrospective study over a period of 18 years, SES information would have been 
impractical to obtain because it was not collected or easily accessible for many patients.   
Patient data were reviewed using a REDCap database, which effectively stores a 
large amount of medical information for many different patients in one place.  One 
weakness of using the REDCap database is that it must be updated manually by trained 
UNC Hospital employees.  This creates a potential “lag” in the data for certain patients at 
Potential Non-Medical 
Influences on Pediatric 
Cancer Survial 
Race 
Ethnicity 
SES Distance Metro/Nonmetro Residence 
Sex 
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any given time.  In addition, the sample included children diagnosed with cancer within 
an 18-year window, and recent advancements in treatment may have given individuals a 
higher chance of survival if diagnosed at a later time, such as in 2017, compared to those 
diagnosed in 2001.  Furthermore, many patients were excluded from this study due to 
incomplete data regarding their cancer diagnoses or demographic information.  
Considering the primary purpose of the REDCap database used for this project is for 
internal feasibility, quality improvement, and the possibility of opening new clinical trials 
within the Division of Pediatric Hematology Oncology (PHO) at the UNC Hospital, data 
entry may have been biased to accomplish these goals.  Hopefully this study may lead to 
revisions in this database in order to reduce future limitations by widening the enrollment 
criteria and carrying out more frequent updates.  
In addition, this study had restricted generalizability because only UNC Hospital 
patients were included.  Not every NC resident diagnosed with cancer is treated at UNC 
Hospital as there are other competitor hospitals within the state, including major 
treatment centers located in Durham, NC (Duke Children’s Hospital) and Wake Forest, 
NC (Brenner Children’s Hospital).  In addition, it may be more convenient for families to 
seek treatment in a different state if they live near the NC border.  Also, considering UNC 
Hospital plays a role as a safety-net institution, certain demographic groups may be over 
or underrepresented in the patient population compared to the state as a whole.  
Nonetheless, these findings may be useful for identifying areas for improvement in 
patient care.   
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Considering the regression analyses for the entire sample as well as the ALL case 
study came to similar conclusions, it is likely that the ALL patients influenced the data 
set in a significant way.  Unfortunately, there were not enough patients in the other 
cancer groups (AML, CNS, neuroblastoma, rhabdomyosarcoma, and Wilms tumor) for 
meaningful regression tests to be performed on each cancer type to further explore this 
assertion.  Each year, ALL diagnoses account for approximately 30% of all pediatric 
cancer diagnoses in the US, making it the most common childhood malignancy (“Top 5 
Pediatric Cancers,” 2012).  In this sample, almost 60% of patients had an ALL diagnosis, 
which is about twice that of the US national average (“SEER 5-Year Relative Survival,” 
2014).  This likely contributed to a bias in the sample selection.  
To address the geographic, financial, and transportation burdens for pediatric 
cancer patients and their families, several potential solutions may lessen their impact.  
Patients should be encouraged to receive treatment and follow-up care at the closest 
facility possible, rather than routinely traveling to treatment centers that are significantly 
further away.  Another possible solution could be the creation of additional specialty 
clinics throughout the state, giving patients more options and the opportunity to limit 
travel distances.  These clinics could share space with other providers and only operate a 
few days per week to reduce expenses.  Expanded state and county-level highway and 
public transportation systems could also help reduce travel times.  Government or 
privately sponsored programs to assist with transportation costs (such as for gas 
expenses) could provide certain patient populations with much-needed support.  
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For patients without access to private transportation, hospital shuttle programs 
could be created to pick patients up at specified locations and take them directly to the 
UNC Hospital.  This program would benefit a wide range of patients treated at the UNC 
Hospital, particularly as the institution is committed to serving all demographics 
throughout the state as mentioned previously.  Considering UNC Hospital is a state 
institution, government transportation programs can also be expanded or created.  
Although this may already be the case, providers should also make a conscious effort to 
understand the child’s social situation and identify possible non-medical factors that may 
influence the patient’s prognosis (Figure 10) in an effort to treat him or her more 
effectively.  
To further address lodging issues, additional Ronald McDonald or State 
Employees Credit Union (SECU) family houses could be built to provide patients and 
their families with a reliable and affordable place to stay while their child is undergoing 
cancer therapy.  Government programs can also help subsidize the cost for families 
staying at local hotels.  In addition, providers can make an effort to treat these patients 
either on Friday or over the weekend to help reduce work disruptions for the parents and 
missing school days for the pediatric patient and siblings.  This would also reduce 
childcare costs for the parents, as younger siblings can join their family at the hospital 
without missing school.  
As mentioned previously, pediatric cancer is the number one cause of death by 
disease among children in the US (“Cancer in Children and Adolescents,” 2018).  
However, relatively few studies have been conducted that analyze the influence of 
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geography on pediatric cancer survival outcomes, especially in NC.  One reason for this 
lack of research may be due to the relative rarity of pediatric cancer, which accounts for 
less than 1% of all cancer diagnoses in the United States (Holmes et al, 2015; “Key 
Statistics for Childhood Cancers,” 2018).  Despite its rarity, the physical, emotional, and 
financial toll childhood malignancies have on the patient and family are significant, and 
the severity of this group of diseases warrants the allocation of significant time and 
resources to improve treatment methods and one day find a cure.   
In conclusion, this study showed that certain non-medical factors can influence 
pediatric cancer survival.  Although this study found there to be no significant association 
between distance to the UNC Hospital and survival outcome, other non-medical factors 
such as race and the metropolitan/non-metropolitan classification of a patient’s NC 
county of residence were linked with survival disparities.  Future studies are needed to 
further investigate these variables and to develop more successful treatment programs for 
pediatric cancer patients throughout NC.  
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